Barclays Maintains Overweight on Exelixis, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson has maintained an Overweight rating on Exelixis (NASDAQ:EXEL) and increased the price target from $24 to $25.
January 30, 2024 | 10:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays has reaffirmed its Overweight rating on Exelixis and raised the price target to $25, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst like Peter Lawson suggests a bullish view on Exelixis's future performance. This can often lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100